Want to join the conversation?
$ABBV's global HUMIRA sales for 1Q16 increased 19.2% on operational basis, excluding impact of FX. Strong U.S. HUMIRA growth of 31.9% was driven by continued momentum across all three major market categories rheumatology, dermatology and gastroenterology. International HUMIRA sales growth was also strong, up 11.9% YoverY on operational basis.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.